Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

This study has suspended participant recruitment.
(DSMB)
Sponsor:
Collaborator:
Schering-Plough
Information provided by:
Novacea
ClinicalTrials.gov Identifier:
NCT00536770
First received: September 26, 2007
Last updated: November 2, 2007
Last verified: November 2007

September 26, 2007
November 2, 2007
September 2007
Not Provided
Overall survival rate at 6 months
Same as current
Complete list of historical versions of study NCT00536770 on ClinicalTrials.gov Archive Site
  • Objective response rate
  • Duration of progression free survival
  • Duration of overall survival
Same as current
Not Provided
Not Provided
 
A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
A Randomized Phase 2 Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Subjects With Advanced Pancreatic Adenocarcinoma

The purpose of this study is to determine the safety and efficacy of an investigational study drug DN-101 (calcitriol) when given in combination with gemcitabine ± erlotinib in the treatment of pancreatic cancer.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Pancreatic Cancer
  • Drug: placebo + gemcitabine + erlotinib
  • Drug: Placebo + gemcitabine
  • Drug: calcitriol + gemcitabine
  • Drug: calcitriol + gemcitabine + erlotinib
  • Placebo Comparator: A
    Placebo + gemcitabine
    Intervention: Drug: Placebo + gemcitabine
  • Placebo Comparator: B
    Placebo + gemcitabine + erlotinib
    Intervention: Drug: placebo + gemcitabine + erlotinib
  • Active Comparator: C
    DN-101 + gemcitabine
    Intervention: Drug: calcitriol + gemcitabine
  • Active Comparator: D
    DN-101 + gemcitabine + erlotinib
    Intervention: Drug: calcitriol + gemcitabine + erlotinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
132
Not Provided
Not Provided

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of locally advanced and unresectable, or metastatic pancreatic cancer
  • Performance status 0, 1,or 2
  • Adequate bone marrow, renal and hepatic function

Exclusion Criteria:

  • Prior chemotherapy or radiation therapy for pancreatic cancer
  • Prior treatment for other cancers in last 6 months
  • Cancer of the brain or spine
  • Active uncontrolled infection
  • Hypercalcemia
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00536770
011-017
No
Not Provided
Novacea
Schering-Plough
Not Provided
Novacea
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP